These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 15918196

  • 1. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
    Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL.
    World J Gastroenterol; 2005 May 28; 11(20):3091-8. PubMed ID: 15918196
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A, Wruble LD, Humphries TJ.
    Am J Gastroenterol; 2000 Aug 28; 95(8):1894-9. PubMed ID: 10950032
    [Abstract] [Full Text] [Related]

  • 3. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar 28; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 4. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Jan 28; 13(1):49-57. PubMed ID: 9892879
    [Abstract] [Full Text] [Related]

  • 5. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S.
    Am J Gastroenterol; 2002 Jun 28; 97(6):1332-9. PubMed ID: 12094846
    [Abstract] [Full Text] [Related]

  • 6. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
    Eggleston A, Katelaris PH, Nandurkar S, Thorpe P, Holtmann G, Treat Study Group.
    Aliment Pharmacol Ther; 2009 May 01; 29(9):967-78. PubMed ID: 19210493
    [Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL.
    Aliment Pharmacol Ther; 2002 Mar 01; 16(3):479-85. PubMed ID: 11876701
    [Abstract] [Full Text] [Related]

  • 8. 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms.
    Gillessen A, Beil W, Modlin IM, Gatz G, Hole U.
    J Clin Gastroenterol; 2004 Apr 01; 38(4):332-40. PubMed ID: 15087692
    [Abstract] [Full Text] [Related]

  • 9. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC, Cohen G, Humphries TJ.
    Scand J Gastroenterol; 2000 Dec 01; 35(12):1245-50. PubMed ID: 11199361
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
    Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M, Fujiwara Y, Wada T, Nagahara A, Hongo M, Chiba T, Kinoshita Y, ACID-RELATED SYMPTOM (ARS) RESEARCH GROUP.
    Aliment Pharmacol Ther; 2007 Jul 01; 26(1):69-77. PubMed ID: 17555423
    [Abstract] [Full Text] [Related]

  • 11. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
    Kobeissy AA, Hashash JG, Jamali FR, Skoury AM, Haddad R, El-Samad S, Ladki R, Aswad R, Soweid AM.
    World J Gastroenterol; 2012 May 21; 18(19):2390-5. PubMed ID: 22654431
    [Abstract] [Full Text] [Related]

  • 12. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
    Moraes-Filho JP, Pedroso M, Quigley EM, PAMES Study Group.
    Aliment Pharmacol Ther; 2014 Jan 21; 39(1):47-56. PubMed ID: 24299323
    [Abstract] [Full Text] [Related]

  • 13. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
    Morozov SV, Tsodikova OM, Isakov VA, Gushchin AE, Shipulin GA.
    Eksp Klin Gastroenterol; 2003 Jan 21; (6):58-63, 154. PubMed ID: 15065530
    [Abstract] [Full Text] [Related]

  • 14. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
    Kinoshita Y, Ashida K, Hongo M, Japan Rabeprazole Study Group for NERD.
    Aliment Pharmacol Ther; 2011 Jan 21; 33(2):213-24. PubMed ID: 21083596
    [Abstract] [Full Text] [Related]

  • 15. Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
    Ashida K, Kinoshita Y, Hongo M, Japan Rabeprazole Study Group for NERD.
    Dig Dis Sci; 2011 Aug 21; 56(8):2333-42. PubMed ID: 21302138
    [Abstract] [Full Text] [Related]

  • 16. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y.
    Aliment Pharmacol Ther; 2011 Jan 21; 33(2):203-12. PubMed ID: 21114792
    [Abstract] [Full Text] [Related]

  • 17. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 18. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K, Lind T, Wilder-Smith C.
    Eur J Clin Pharmacol; 2004 Oct 01; 60(8):531-9. PubMed ID: 15349707
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
    Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S.
    Dig Dis Sci; 2005 Nov 01; 50(11):2009-18. PubMed ID: 16240208
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD, European Rabeprazole Study Group.
    Aliment Pharmacol Ther; 2003 Feb 01; 17(3):343-51. PubMed ID: 12562446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.